Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Obstructive hypertrophic cardiomyopathy was a beta-blocker, calcium channel blocker, disopyramide, and septal-reduction-procedure category. Mavacamten (cardiac myosin inhibitor) has established the modern medical therapy, aficamten brings a follow-on with a different pharmacokinetic profile, and additional cardiac myosin modulator programs are in late-stage trials. The category has gone from procedural-default to medical-therapy-led for symptomatic obstructive HCM.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- SnapshotHFrEF therapy reference (2026)
- ExplainedWhat is heart failure?